Form 4: CG Oncology Director Sells Shares After Option Exercise

CG Oncology Director James Mulay exercised stock options and subsequently sold 12,755 shares of common stock for a weighted average price of $39.19 per share.

Summary

• James Mulay, a Director of CG Oncology, Inc. (CGON), engaged in a transaction involving the company's common stock.
• On September 29, 2025, Mulay exercised a Director Stock Option to acquire 12,755 shares of common stock at an exercise price of $1.82 per share.
• Concurrently, on the same date, he sold all 12,755 shares of common stock.
• The shares were sold at a weighted average price of $39.19 per share, with individual transaction prices ranging from $38.99 to $39.41.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mulay on June 6, 2025.
• Following these transactions, Mulay beneficially owns 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction where a director exercised options and sold shares under a pre-arranged trading plan. This is generally neutral, though some investors may view insider selling as a minor negative.

Positives

• Director Mulay realized a significant gain by exercising options at $1.82 and selling shares at a weighted average of $39.19.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating planned and compliant insider trading.

Negatives

• A director selling shares could be perceived negatively by some investors, as it reduces their direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, though it was pre-planned. No direct impact on company operations or value.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a director following an option exercise. While insider selling can sometimes be a bearish signal, this transaction was executed under a Rule 10b5-1 plan, suggesting it was not based on new, material non-public information. Therefore, it is unlikely to fundamentally alter the company's investment profile on its own, warranting a 'hold' recommendation for existing positions while monitoring future developments.

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director, James Mulay, Rule 10b5-1